PMGroup
PME
Comm
uniqué
T40
Quality in Care
How to Advertise
Privacy and cookies
My Account
Register
Please login to the form below
Not currently logged in
Email:
Password:
I have forgotten my password
CROs and trial design
Early access and regulation
Value demonstration
Strategic communications
Strategic communications
Orphan drug firm Sobi opens new European base
Company'sBrussels office will also house its Benelux operations
Orphan drug market to reach $176bn by 2020
New report suggests market will almost double in five years
Channel strategy and orphan drugs
A plan for guiding decisions about a product's distribution channel is particularly relevant for orphan drugs, rare diseases or specialty medicines
The distressing impact of rare diseases
Much more needs to be done to address the problem of effective communications with stakeholders and adequate information for patients affected
Orphan drugs: A 'responsible' investment
There's growing sense of responsibility in the orphan drug market, but the market remains under-exploited by companies
Small diseases need big picture communications
An early commitment to communications planning in rare diseases is worth the risk
Novartis sponsors rare disease patient community
Backs site for patients affected by pancreatic neuroendocrine tumours (PNET)
Rare disease patients face 5-7 year wait for diagnosis
Doctors often lack time and resources to manage patients
Novartis provides multimedia support to Rare Diseases Day
Collaborates with Eurordis on multimedia education campaign
Shining a light on orphan medicines
Orphan diseases represent one of the most exciting and emotive areas in modern medicine and need a communications strategy that covers a spectrum of issues
1